{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:47:35Z","timestamp":1787237255200,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05338-x","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T06:02:25Z","timestamp":1730354545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Ankit","family":"Sachan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Pethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amlesh","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"5338_CR1","doi-asserted-by":"crossref","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Comperat E et al (2013) EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 64:639\u2013653","DOI":"10.1016\/j.eururo.2013.06.003"},{"key":"5338_CR2","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progressionin individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013477","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"5338_CR3","first-page":"CD003231","volume":"3","author":"MD Shelley","year":"2003","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 3:CD003231","journal-title":"Cochrane Database Syst Rev"},{"key":"5338_CR4","doi-asserted-by":"crossref","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, Van De Beek C, Van Andel G et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63:462\u2013472","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"5338_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","volume":"66","author":"AM Nieder","year":"2005","unstructured":"Nieder AM, Brausi M, Lamm D, O\u2019Donnell M, Tomita K, Woo H et al (2005) Management of stage T1 tumors of the bladder: international consensus panel. Urology 66:108\u2013125","journal-title":"Urology"},{"key":"5338_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrurol.2014.52","volume":"11","author":"H Zargar","year":"2014","unstructured":"Zargar H, Aning J, Ischia J, So A, Black P (2014) Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol 11:220\u2013230","journal-title":"NatRev Urol"},{"key":"5338_CR7","first-page":"1149","volume":"24","author":"EN Rampersaud","year":"2010","unstructured":"Rampersaud EN, Vujaskovic Z, Inman BA (2010) Hyperthermia as a treatment for bladder cancer. Oncol York 24:1149\u20131155","journal-title":"Oncol York"},{"key":"5338_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1464-410X.1993.tb06480.x","volume":"72","author":"PD Abdel","year":"1993","unstructured":"Abdel PD (1993) Follow-up of patients with superficial transitional cell carcinoma of the bladder.Case for change in policy. Br J Urol 72:125\u2013130","journal-title":"Br J Urol"},{"key":"5338_CR9","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182:2195","journal-title":"J Urol"},{"key":"5338_CR10","first-page":"709","volume":"53","author":"RJ Sylvester","year":"2008","unstructured":"Sylvester RJ, Oosterlinck W, Witjes JA (2008) The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53:709","journal-title":"EurUrol"},{"key":"5338_CR11","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","volume":"21","author":"R Colombo","year":"2003","unstructured":"Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J et al (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270\u20134276","journal-title":"J Clin Oncol"},{"key":"5338_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","volume":"107","author":"R Colombo","year":"2011","unstructured":"Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D (2011) Long-term outcomes of a randomized controlled trial comparing thermo-chemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107:912\u2013918","journal-title":"BJU Int"},{"key":"5338_CR13","doi-asserted-by":"crossref","unstructured":"Van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z et al (2004) Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 46:65\u201371; discussion 71\u20132","DOI":"10.1016\/j.eururo.2004.01.019"},{"issue":"4","key":"5338_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","volume":"40","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos F, Gonz\u00e1lez-Padilla DA, Gonz\u00e1lez-D\u00edaz A, de la Rosa-Kehrmann F, Rodr\u00edguez-Antol\u00edn A, Inman BA et al (2022) Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol 40(4):999\u20131004","journal-title":"World J Urol"},{"issue":"6","key":"5338_CR15","first-page":"497","volume":"83","author":"WS Tan","year":"2023","unstructured":"Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P et al (2023) Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur Urol 83(6):497\u2013504","journal-title":"EurUrol"},{"issue":"6","key":"5338_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus calmette-gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69(6):1046\u20131052","journal-title":"Eur Urol"},{"issue":"3","key":"5338_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s13193-024-01950-w","volume":"15","author":"P Singh","year":"2024","unstructured":"Singh P, Sachan A, Nayak B, Nayyar R, Kumar R, Seth A (2024) Comparative analysis of clinicopathologic characteristics and outcomes of urothelial bladder cancer between young and older adults-experience from a tertiary care center. Indian J Surg Oncol 15(3):563\u2013571","journal-title":"Indian J Surg Oncol"},{"issue":"7","key":"5338_CR18","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.7314\/APJCP.2015.16.7.2675","volume":"16","author":"N Mehta","year":"2015","unstructured":"Mehta N, Rathore RS, Pillai BS, Sam MP, Moorthy K (2015) Intrinsic tumour factors affecting recurrence in non muscle invasive bladder cancer: a hospital based study from India. Asian Pac J Cancer Prev 16(7):2675\u20132677","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05338-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:25:37Z","timestamp":1735835137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05338-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5338"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05338-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}